Current status of Chagas disease chemotherapy

References

• Chagas C. Nova tripanozomiase humana. Estudos sobre a morfolojía e o ciclo evolutivo de Schizotrypanum cruzi n. gen., n. sp., ajente etiolójico de nova entidade morbida do homen. Mem. Inst. Oswaldo Cruz1, 159–218 (1909).
   Google Scholar
• Zingales B, Andrade SG, Briones MR et al. A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Mem. Inst. Oswaldo Cruz104(7), 1051–1054 (2009).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Control of Chagas’ disease: Second Report of the Expert Committee. WHO Technical Report Series. WHO, Geneva, Switzerland, 905 (2002).
   Google Scholar
• Moncayo A, Silveira AC. Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 17–30 (2009).
   PubMed Web of Science ®Google Scholar
• Salvatella R. Andean subregional Chagas disease area and the Andean initiative of Chagas disease. Mem. Inst. Oswaldo Cruz102(Suppl. 1), 39–40 (2007).
   PubMedGoogle Scholar
• Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet375(9723), 1388–1402 (2010).
   PubMed Web of Science ®Google Scholar
• Pinto Dias JC. Natural history of Chagas disease. Arq. Bras. Cardiol.65(4), 359–366 (1995).
   PubMedGoogle Scholar
• Higuchi Y, Otsu K, Nishida K et al. The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-κ B. J. Biol. Chem.278(23), 20770–20777 (2003).
   PubMedGoogle Scholar
• Tafuri WL. Pathogenesis of Chagas’ disease. Rev. Inst. Med. Trop. Sao Paulo29(4), 194–199 (1987).
   PubMedGoogle Scholar
• Leon JS, Wang K, Engman DM. Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas’ disease. J. Immunol.171(8), 4271–4277 (2003).
   PubMed Web of Science ®Google Scholar
• Bellotti G, Bocchi EA, De Moraes AV et al. In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas’ heart disease. Am. Heart J.131(2), 301–307 (1996).
   PubMed Web of Science ®Google Scholar
• Higuchi ML. Chagas disease. Importance of the parasite in the pathogenesis of the cardiac chronic disease. Arq. Bras. Cardiol.64(3), 251–254 (1995).
   PubMedGoogle Scholar
• Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, Mccurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am. J. Trop. Med. Hyg.48(3), 348–357 (1993).
   PubMed Web of Science ®Google Scholar
• Anez N, Carrasco H, Parada H et al. Myocardial parasite persistence in chronic chagasic patients. Am. J. Trop. Med. Hyg.60(5), 726–732 (1999).
   PubMed Web of Science ®Google Scholar
• Lages-Silva E, Crema E, Ramirez LE, Macedo AM, Pena SD, Chiari E. Relationship between Trypanosoma cruzi and human chagasic megaesophagus: blood and tissue parasitism. Am. J. Trop. Med. Hyg.65(5), 435–441 (2001).
   PubMedGoogle Scholar
• Vago AR, Macedo AM, Adad SJ, Reis DD, Correa-Oliveira R. PCR detection of Trypanosoma cruzi DNA in oesophageal tissues of patients with chronic digestive Chagas’ disease. Lancet348(9031), 891–892 (1996).
   PubMed Web of Science ®Google Scholar
• Leon JS, Engman DM. Autoimmunity in Chagas heart disease. Int. J. Parasitol.31(5–6), 555–561 (2001).
   PubMed Web of Science ®Google Scholar
• Kierszenbaum F. Chagas’ disease and the autoimmunity hypothesis. Clin. Microbiol. Rev.12(2), 210–223 (1999).
   PubMed Web of Science ®Google Scholar
• Cossio PM, Laguens RP, Diez C, Szarfman A, Segal A, Arana RM. Chagasic cardiopathy. Antibodies reacting with plasma membrane of striated muscle and endothelial cells. Circulation50(6), 1252–1259 (1974).
   PubMedGoogle Scholar
• Anselmi A, Pifano F, Suarez JA, Gurdiel O. Myocardiopathy in Chagas’ disease. I. Comparative study of pathologic findings in chronic human and experimental Chagas’ myocarditis. Am. Heart J.72(4), 469–481 (1966).
   PubMedGoogle Scholar
• Lopez Bergami P, Scaglione J, Levin MJ. Antibodies against the carboxyl-terminal end of the Trypanosoma cruzi ribosomal P proteins are pathogenic. FASEB J.15(14), 2602–2612 (2001).
   PubMedGoogle Scholar
• Levin MJ, Mesri E, Benarous R et al. Identification of major Trypanosoma cruzi antigenic determinants in chronic Chagas’ heart disease. Am. J. Trop. Med. Hyg.41(5), 530–538 (1989).
   PubMedGoogle Scholar
• Cunha-Neto E, Coelho V, Guilherme L, Fiorelli A, Stolf N, Kalil J. Autoimmunity in Chagas’ disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas’ cardiomyopathy patient. J. Clin. Invest.98(8), 1709–1712 (1996).
   PubMed Web of Science ®Google Scholar
• Kerner N, Liegeard P, Levin MJ, Hontebeyrie-Joskowicz M. Trypanosoma cruzi: antibodies to a MAP-like protein in chronic Chagas’ disease cross-react with mammalian cytoskeleton. Exp. Parasitol.73(4), 451–459 (1991).
   PubMedGoogle Scholar
• Petry K, Eisen H. Chagas disease: a model for the study of autoimmune diseases. Parasitol. Today5(4), 111–116 (1989).
   PubMedGoogle Scholar
• Rizzo LV, Cunha-Neto E, Teixeira AR. Autoimmunity in Chagas’ disease: specific inhibition of reactivity of CD4+ T cells against myosin in mice chronically infected with Trypanosoma cruzi. Infect. Immun.57(9), 2640–2644 (1989).
   PubMedGoogle Scholar
• Ribeiro-Dos-Santos R, Mengel JO, Postol E et al. A heart-specific CD4+ T-cell line obtained from a chronic chagasic mouse induces carditis in heart-immunized mice and rejection of normal heart transplants in the absence of Trypanosoma cruzi. Parasite Immunol.23(2), 93–101 (2001).
   PubMedGoogle Scholar
• Girones N, Fresno M. Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? Trends Parasitol.19(1), 19–22 (2003).
   PubMed Web of Science ®Google Scholar
• Rowland E, Luo H, Mccormick T. Infection characteristics of an Ecuadorian Trypanosoma cruzi strain with reduced virulence. J. Parasitol.81(1), 123–126 (1995).
   PubMedGoogle Scholar
• Higuchi ML, De Brito T, Reis MM. Correlation between T.cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovasc. Pathol.2, 101–106 (1993).
   PubMed Web of Science ®Google Scholar
• Barbosa AJ, Gobbi H, Lino BT et al. Comparative study of the conventional method and the peroxidase-antiperoxidase method in the search for tissue parasitism in chronic Chagas’ cardiopathy. Rev. Inst. Med. Trop. Sao Paulo28(2), 91–96 (1986).
   PubMedGoogle Scholar
• Lana M, Lopes LA, Martins HR et al. Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Mem. Inst. Oswaldo Cruz104(8), 1139–1147 (2009).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas’ disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am. Heart J.127(1), 151–162 (1994).
   PubMed Web of Science ®Google Scholar
• Lauria-Pires L, Braga MS, Vexenat AC et al. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. Am. J. Trop. Med. Hyg.63(3–4), 111–118 (2000).
   PubMed Web of Science ®Google Scholar
• Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo4, 389–396 (1962).
   PubMedGoogle Scholar
• Haberkorn A, Gonnert R. Animal experimental investigation into the activity of nifurtimox against Trypanosoma cruzi. Arzneimittelforschung22(9), 1570–1582 (1972).
   PubMedGoogle Scholar
• Raaflaub J, Ziegler WH. Single-dose pharmacokinetics of the trypanosomicide benznidazole in man. Arzneimittelforschung29(10), 1611–1614 (1979).
   PubMed Web of Science ®Google Scholar
• Guedes PMM, Fietto JLR, Lana M, Bahia MT. Advances in Chagas disease chemotherapy. Anti-Infective Agents in Medicinal Chemistry5(2), 11 (2006).
   Google Scholar
• Docampo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interact.73(1), 1–27 (1990).
   PubMed Web of Science ®Google Scholar
• Stoppani AO. The chemotherapy of Chagas disease. Medicina (B. Aires)59(Suppl. 2), 147–165 (1999).
   PubMedGoogle Scholar
• Docampo R, Moreno SN, Turrens JF, Katzin AM, Gonzalez-Cappa SM, Stoppani AO. Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Mol. Biochem. Parasitol.3(3), 169–180 (1981).
   PubMed Web of Science ®Google Scholar
• Ministério da Saúde. Secretaria de Vigilância em Saúde. Brazilian Consensus on Chagas disease. Rev. Soc. Bras. Med. Trop.38(Suppl. 3), 7–29 (2005).
   Web of Science ®Google Scholar
• Russomando G, De Tomassone MM, De Guillen I et al. Treatment of congenital Chagas’ disease diagnosed and followed up by the polymerase chain reaction. Am. J. Trop. Med. Hyg.59(3), 487–491 (1998).
   PubMed Web of Science ®Google Scholar
• Blanco SB, Segura EL, Cura EN et al. Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Trop. Med. Int. Health5(4), 293–301 (2000).
   PubMed Web of Science ®Google Scholar
• Schijman AG, Altcheh J, Burgos JM et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. J. Antimicrob. Chemother.52(3), 441–449 (2003).
   PubMed Web of Science ®Google Scholar
• Burgos JM, Altcheh J, Petrucelli N et al. Molecular diagnosis and treatment monitoring of congenital transmission of Trypanosoma cruzi to twins of a triplet delivery. Diagn. Microbiol. Infect. Dis.65(1), 58–61 (2009).
   PubMed Web of Science ®Google Scholar
• Shikanai-Yasuda MA, Lopes MH, Tolezano JE et al. Acute Chagas’ disease: transmission routes, clinical aspects and response to specific therapy in diagnosed cases in an urban center. Rev. Inst. Med. Trop. Sao Paulo32(1), 16–27 (1990).
   PubMed Web of Science ®Google Scholar
• Andrade SG, Rassi A, Magalhaes JB, Ferriolli Filho F, Luquetti AO. Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Trans. R. Soc. Trop. Med. Hyg.86(6), 624–626 (1992).
   PubMed Web of Science ®Google Scholar
• Bahia-Oliveira LM, Gomes JA, Cancado JR et al. Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14–30 years ago. J. Infect. Dis.182(2), 634–638 (2000).
   PubMed Web of Science ®Google Scholar
• Cançado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev. Inst. Med. Trop. Sao Paulo44(1), 29–37 (2002).
   PubMedGoogle Scholar
• De Andrade AL, Zicker F, De Oliveira RM et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet348(9039), 1407–1413 (1996).
   PubMed Web of Science ®Google Scholar
• Andrade AL, Martelli CM, Oliveira RM et al. Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. Am. J. Trop. Med. Hyg.71(5), 594–597 (2004).
   PubMed Web of Science ®Google Scholar
• Silveira CA, Castillo E, Castro C. Evaluation of an specific treatment for Trypanosoma cruzi in children, in the evolution of the indeterminate phase. Rev. Soc. Bras. Med. Trop.33(2), 191–196 (2000).
   PubMedGoogle Scholar
• Andrade SG, Magalhaes JB. Biodemes and zymodemes of Trypanosoma cruzi strains: correlations with clinical data and experimental pathology. Rev. Soc. Bras. Med. Trop.30(1), 27–35 (1996).
   PubMedGoogle Scholar
• Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am. J. Trop. Med. Hyg.59(4), 526–529 (1998).
   PubMed Web of Science ®Google Scholar
• Sosa Estani S, Segura EL. Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Mem. Inst. Oswaldo Cruz94(Suppl. 1), 363–365 (1999).
   PubMed Web of Science ®Google Scholar
• Silveira AC. Current situation with chagas disease vector control in the Americas. Cad. Saude Publica16(Suppl. 2), 35–42 (2000).
   PubMedGoogle Scholar
• Streiger ML, Del Barco ML, Fabbro DL, Arias ED, Amicone NA. Longitudinal study and specific chemotherapy in children with chronic Chagas’ disease, residing in a low endemicity area of Argentina. Rev. Soc. Bras. Med. Trop.37(5), 365–375 (2004).
   PubMedGoogle Scholar
• Escriba JM, Ponce E, Romero Ade D et al. Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Mem. Inst. Oswaldo Cruz104(7), 986–991 (2009).
   PubMed Web of Science ®Google Scholar
• Torrico F, Alonso-Vega C, Suarez E et al. Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am. J. Trop. Med. Hyg.70(2), 201–209 (2004).
   PubMed Web of Science ®Google Scholar
• Chippaux JP, Clavijo AN, Santalla JA, Postigo JR, Schneider D, Brutus L. Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole. Trop. Med. Int. Health15(1), 87–93 (2010).
   PubMed Web of Science ®Google Scholar
• Freilij H, Altcheh J. Congenital Chagas’ disease: diagnostic and clinical aspects. Clin. Infect. Dis.21(3), 551–555 (1995).
   PubMed Web of Science ®Google Scholar
• Ferreira Hde O. Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole. Rev. Soc. Bras. Med. Trop.23(4), 209–211 (1990).
   PubMedGoogle Scholar
• Fabbro De Suasnabar D, Arias E, Streiger M et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev. Inst. Med. Trop. Sao Paulo42(2), 99–109 (2000).
   PubMedGoogle Scholar
• Braga MS, Lauria-Pires L, Arganaraz ER, Nascimento RJ, Teixeira AR. Persistent infections in chronic Chagas’ disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Rev. Inst. Med. Trop. Sao Paulo42(3), 157–161 (2000).
   PubMedGoogle Scholar
• Ferreira LR, Abrantes EF, Rodrigues CV et al. Identification and characterization of a novel mouse gene encoding a Ras-associated guanine nucleotide exchange factor: expression in macrophages and myocarditis elicited by Trypanosoma cruzi parasites. J. Leukoc. Biol.72(6), 1215–1227 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandes CD, Tiecher FM, Balbinot MM et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem. Inst. Oswaldo Cruz104(1), 27–32 (2009).
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi A Jr, Morillo CA et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: the Benznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am. Heart J.156(1), 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Galvao LM, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J. Clin. Microbiol.41(11), 5066–5070 (2003).
   PubMed Web of Science ®Google Scholar
• Martins-Filho OA, Pereira ME, Carvalho JF, Cancado JR, Brener Z. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas’ disease. Clin. Diagn. Lab. Immunol.2(5), 569–573 (1995).
   PubMedGoogle Scholar
• Krettli AU, Weisz-Carrington P, Nussenzweig RS. Membrane-bound antibodies to bloodstream Trypanosoma cruzi in mice: strain differences in susceptibility to complement-mediated lysis. Clin. Exp. Immunol.37(3), 416–423 (1979).
   PubMedGoogle Scholar
• Norris KA, Galvao LM, Schrimpf JE, Cancado JR, Krettli AU. Humoral immune response to the Trypanosoma cruzi complement regulatory protein as an indicator of parasitologic clearance in human Chagas’ disease. Infect. Immun.62(9), 4072–4074 (1994).
   PubMedGoogle Scholar
• Galvao LM, Nunes RM, Cancado JR, Brener Z, Krettli AU. Lytic antibody titre as a means of assessing cure after treatment of Chagas disease: a 10 years follow-up study. Trans. R. Soc. Trop. Med. Hyg.87(2), 220–223 (1993).
   PubMed Web of Science ®Google Scholar
• Krettli AU, Cancado JR, Brener Z. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas’s disease. Trans. R. Soc. Trop. Med. Hyg.76(3), 334–340 (1982).
   PubMed Web of Science ®Google Scholar
• Guedes PM, Veloso VM, Tafuri WL et al. The dog as model for chemotherapy of the Chagas’ disease. Acta Trop.84(1), 9–17 (2002).
   PubMed Web of Science ®Google Scholar
• Andrade SG, Freitas LA, Peyrol S, Pimentel AR, Sadigursky M. Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bull. World Health Organ.69(2), 191–197 (1991).
   PubMed Web of Science ®Google Scholar
• Portella RS, Andrade SG. Trypanosoma cruzi: parasite antigens sequestered in heart interstitial dendritic cells are related to persisting myocarditis in benznidazole-treated mice. Mem. Inst. Oswaldo Cruz104(7), 1023–1030 (2009).
   PubMedGoogle Scholar
• Olivieri BP, Molina JT, De Castro SL et al. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. Int. J. Antimicrob Agents36(1), 79–83 (2010).
   PubMedGoogle Scholar
• Guedes PM, Oliveira FS, Gutierrez FR et al. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas’ disease. Br. J. Pharmacol.160(2), 270–282 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia S, Ramos CO, Senra JF et al. Treatment with benznidazole during the chronic phase of experimental Chagas’ disease decreases cardiac alterations. Antimicrob. Agents Chemother.49(4), 1521–1528 (2005).
   PubMed Web of Science ®Google Scholar
• Caldas IS, Talvani A, Caldas S et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol. Res.103(2), 413–421 (2008).
   PubMed Web of Science ®Google Scholar
• Corrales M, Cardozo R, Segura MA, Urbina JA, Basombrio MA. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas’ disease. Antimicrob. Agents Chemother.49(4), 1556–1560 (2005).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Payares G, Sanoja C et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob Agents21(1), 39–48 (2003).
   PubMed Web of Science ®Google Scholar
• Molina J, Martins-Filho O, Brener Z, Romanha AJ, Loebenberg D, Urbina JA. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob. Agents Chemother.44(1), 150–155 (2000).
   PubMed Web of Science ®Google Scholar
• Diniz Lde F, Caldas IS, Guedes PM et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob. Agents Chemother.54(7), 2979–2986 (2010).
   PubMed Web of Science ®Google Scholar
• Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann. Intern. Med.144(10), 724–734 (2006).
   PubMed Web of Science ®Google Scholar
• Marin-Neto JA, Rassi A Jr, Avezum A Jr et al. The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 319–324 (2009).
   PubMed Web of Science ®Google Scholar
• Silva JJ, Pavanelli WR, Pereira JC, Silva JS, Franco DW. Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors. Antimicrob. Agents Chemother.53(10), 4414–4421 (2009).
   PubMedGoogle Scholar
• Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 311–318 (2009).
   PubMed Web of Science ®Google Scholar
• Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009–2010. Curr. Opin. Infect. Dis.23(6), 609–616 (2010).
   PubMedGoogle Scholar
• Urbina JA, Vivas J, Ramos H, Larralde G, Aguilar Z, Avilan L. Alteration of lipid order profile and permeability of plasma membranes from Trypanosoma cruzi epimastigotes grown in the presence of ketoconazole. Mol. Biochem. Parasitol.30(2), 185–195 (1988).
   PubMedGoogle Scholar
• Urbina JA, Lazardi K, Larralde G, Aguirre T, Piras MM, Piras R. Synergistic effects of ketoconazole and SF-86327 on the proliferation of epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Ann. NY Acad. Sci.544, 357–358 (1988).
   PubMedGoogle Scholar
• Urbina JA, Marchan E, Lazardi K et al. Inhibition of phosphatidylcholine biosynthesis and cell proliferation in Trypanosoma cruzi by ajoene, an antiplatelet compound isolated from garlic. Biochem. Pharmacol.45(12), 2381–2387 (1993).
   PubMed Web of Science ®Google Scholar
• Clemons KV, Hanson LH, Stevens DA. Activities of the triazole D0870 in vitro and against murine blastomycosis. Antimicrob. Agents Chemother.37(5), 1177–1179 (1993).
   PubMed Web of Science ®Google Scholar
• Laughlin M, Pai S, Menon S et al. SCH 56592: rising multiple-dose safety, tolerance, and pharmacokinetic evaluation in healthy volunteers. Programs and Abstracts of the 37th ICAAC. Toronto, ON, Canada, 28 September–1 October (1997) (Abstract 87).
   Google Scholar
• Mccabe RE, Remington JS, Araujo FG. Ketoconazole inhibition of intracellular multiplication of Trypanosoma cruzi and protection of mice against lethal infection with the organism. J. Infect. Dis.150(4), 594–601 (1984).
   PubMed Web of Science ®Google Scholar
• Mccabe RE, Remington JS, Araujo FG. Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg.81(4), 613–615 (1987).
   PubMedGoogle Scholar
• Brener Z, Cancado JR, Galvao LM et al. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz88(1), 149–153 (1993).
   PubMed Web of Science ®Google Scholar
• Mccabe R. Failure of ketoconazole to cure chronic murine Chagas’ disease. J. Infect. Dis.158(6), 1408–1409 (1988).
   PubMedGoogle Scholar
• Moreira AA, De Souza HB, Amato Neto V et al. Evaluation of the therapeutic activity of itraconazole in chronic infections, experimental and human, by Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo34(2), 177–180 (1992).
   PubMed Web of Science ®Google Scholar
• Maldonado RA, Molina J, Payares G, Urbina JA. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas’ disease. Antimicrob. Agents Chemother.37(6), 1353–1359 (1993).
   PubMed Web of Science ®Google Scholar
• Urbina JA. Parasitological cure of Chagas disease: is it possible? Is it relevant? Mem. Inst. Oswaldo Cruz94(Suppl. 1), 349–355 (1999).
   PubMed Web of Science ®Google Scholar
• Liendo A, Lazardi K, Urbina JA. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi. J. Antimicrob. Chemother.41(2), 197–205 (1998).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Payares G, Contreras LM et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother.42(7), 1771–1777 (1998).
   PubMed Web of Science ®Google Scholar
• Guedes PM, Urbina JA, De Lana M et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob. Agents Chemother.48(11), 4286–4292 (2004).
   PubMed Web of Science ®Google Scholar
• Mikamo H, Yin XH, Hayasaki Y et al. Penetration of ravuconazole, a new triazole antifungal, into rat tissues. Chemotherapy48(1), 7–9 (2002).
   PubMed Web of Science ®Google Scholar
• Andes D. Clinical pharmacodynamics of antifungals. Infect. Dis. Clin. North Am.17(3), 635–649 (2003).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol.19(11), 495–501 (2003).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Lira R, Visbal G, Bartroli J. In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother.44(9), 2498–2502 (2000).
   PubMed Web of Science ®Google Scholar
• Urbina JA, Payares G, Sanoja C, Lira R, Romanha AJ. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents21(1), 27–38 (2003).
   PubMed Web of Science ®Google Scholar
• Urbina JA. New advances in the management of a long-neglected disease. Clin. Infect. Dis.49(11), 1685–1687 (2009).
   PubMed Web of Science ®Google Scholar
• Pinazo MJ, Espinosa G, Gallego M, Lopez-Chejade PL, Urbina JA, Gascon J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am. J. Trop. Med. Hyg.82(4), 583–587 (2010).
   PubMed Web of Science ®Google Scholar
• Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem. Inst. Oswaldo Cruz98(5), 577–591 (2003).
   PubMed Web of Science ®Google Scholar
• Dias JC. Elimination of Chagas disease transmission: perspectives. Mem. Inst. Oswaldo Cruz104(Suppl. 1), 41–45 (2009).
   PubMed Web of Science ®Google Scholar
• WHO. Seventeenth Programme Report of the UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases. WHO, Geneva, Switzerland, 31–33 (2005).
   Google Scholar
• Mccabe RE, Remington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am. J. Trop. Med. Hyg.35(2), 280–284 (1986).
   PubMed Web of Science ®Google Scholar